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Abstract
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder in which the loss of
dystrophin causes progressive degeneration of skeletal and cardiac muscle. Potential therapies that
carry substantial risk, such as gene and cell-based approaches, must first be tested in animal
models, notably the mdx mouse and several dystrophin-deficient breeds of dogs, including golden
retriever muscular dystrophy (GRMD). Affected dogs have a more severe phenotype, in keeping
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with that of DMD, so may better predict disease pathogenesis and treatment efficacy. We and
others have developed various phenotypic tests to characterize disease progression in the GRMD
model. These biomarkers range from measures of strength and joint contractures to magnetic
resonance imaging. Some of these tests are routinely used in clinical veterinary practice, while
others require specialized equipment and expertise. By comparing serial measurements from
treated and untreated groups, one can document improvement or delayed progression of disease.
Potential treatments for DMD may be broadly categorized as molecular, cellular, or
pharmacologic. The GRMD model has increasingly been used to assess efficacy of a range of
these therapies. While some of these studies have largely provided general proof-of-concept for
the treatment under study, others have demonstrated efficacy using the biomarkers discussed.
Importantly, just as symptoms in DMD vary among patients, GRMD dogs display remarkable
phenotypic variation. While confounding statistical analysis in preclinical trials, this variation
offers insight regarding the role that modifier genes play in disease pathogenesis. By correlating
functional and mRNA profiling results, gene targets for therapy development can be identified.
Introduction
Duchenne muscular dystrophy (DMD) is an X-linked recessive disorder affecting
approximately 1 of 3,500-7,500 newborn live human males (Cowan et al 1980) in whom
absence of the protein dystrophin causes progressive degeneration of skeletal and cardiac
muscle (Hoffman et al 1987). Becker muscular dystrophy (BMD), a less severe clinical
form, occurs at approximately one tenth the frequency of DMD (Prior and Bridgeman 2005).
BMD mutations have a similar incidence and distribution to those causing DMD but
maintain the dystrophin reading frame, allowing for production of a truncated, partially-
functional protein. DMD boys are typically confined to wheel chairs before 12 years of age,
while those with BMD walk beyond 16 years (Malhotra et al 1988). Approximately two
thirds of DMD gene mutations have historically been attributed to large (> 1 exon) deletions
(Wulff et al 1989; Prior and Bridgement 2005; Dent et al 2005). These deletions tend to
predominate in one of two hotspots, namely the central rod domain around exons 44-53 (~
80%) and, to a lesser extent (~ 20%), the 5’ terminus (Beggs, 1990; Prior and Bridgement
2005). A recent study in which point mutations identified by sequence analysis were likely
over represented found an incidence of only 43% deletions, 11% duplications, and 46%
point mutations (Flanigan et al 2009). While DMD classically demonstrates a strong family
history, about one third of cases occur due to new mutations (Caskey et al 1980).
Potential therapies that carry substantial risk, such as gene and cell-based approaches, must
ideally first be tested in relevant animal models, most notably the mdx mouse (Bulfield et al
1984; Gillis 1999) and several dystrophin-deficient breeds of dogs (Kornegay et al 1988;
Cooper et al 1988; Schatzberg et al 1999; Jones et al 2004; Baltzer et al 2007; Smith et al
2011). Because clinical features in dogs are more severe than those in mdx mice, in keeping
with the DMD phenotype, preclinical studies in the canine models might be more predictive
of disease pathogenesis and treatment outcome. While numerous dog breeds with
dystrophin-deficient muscular dystrophy have been characterized clinically, few have been
studied at the molecular level. We have conducted extensive studies in a dystrophin-
deficient form of muscular dystrophy originally characterized in golden retrievers (GRMD).
A mRNA processing error in GRMD dogs results from a single base change in the 3’
consensus splice site of intron 6. Exon 7 is consequently skipped during mRNA processing
(Sharp et al 1991). The resulting transcript predicts that the dystrophin reading frame is
terminated within its N-terminal domain in exon 8.
DMD gene mutations have also been described in Rottweilers (nonsense mutation in exon
58) (Winand et al 1994 and Winand N, personal communication), German shorthaired
pointers (large deletion, essentially amounting to a “dystrophin knock out”) (Schatzberg et al
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1999), Welsh corgis (repetitive element-1 [LINE-1] insertion in intron 13) (Smith et al
2011), and Cavalier King Charles Spaniels (missense mutation in the 5’ donor splice site of
exon 50 resulting in deletion of exon 50 in mRNA transcripts) (Walmsley et al 2010) (Table
1). Separately, we have identified three additional DMD gene mutations in the Cocker
spaniel (deletion of four nucleotides in exon 65, with a reading frame shift predicting a
premature stop codon at the site of the deletion), Tibetan terrier (a large deletion of exons
8-29), and Labrador retriever (184 nucleotide [pseudoexon] insertion between exon 19 and
exon 20, which results in a premature stop codon at the next codon downstream of the
insertion) (Larsen CA et al, unpublished). The Labrador retriever mutation presumably
corresponds to one in an earlier report (Smith et al 2007).
Biomarkers for assessment of the natural history and response to
treatment
Clinical course of DMD
The study of muscle diseases has evolved from a classical period in which a diagnosis was
based on clinical and pathologic features, to a modern period when muscle biopsies were
further characterized through histo- and cytochemical techniques, to the current era of
molecular diagnosis (Engel and Osawa 2004; Meola 2005). With the advent of techniques
such as multiplex polymerase chain reaction and Southern blotting, DMD can be diagnosed
non-invasively without the need for muscle biopsy (Prior and Bridgeman 2005). As a result,
baseline and follow-up pathologic data are not typically available to assess disease
progression or response to therapy. Other surrogate biomarkers must be utilized to ensure
that results of treatment trials are interpreted appropriately. Most DMD natural history
studies have included measurements of muscle strength, joint contractures, and timed
function tests. Results from these tests are used to track disease progression and offer insight
on clinical milestones, such as the loss of ambulation and the need for ventilatory support.
Both muscle weakness and joint contractures contribute to postural instability and ultimate
loss of ambulation (Vignos 1963). Contracture and muscle strength scores generally
correlate and deteriorate synchronously over time (Brooke et al 1983).
Clinical course of GRMD
Several studies have defined the characteristic clinical signs of GRMD (Kornegay et al
1988; Valentine et al 1988; Shimatsu et al 2005; Ambrósio et al 2009) (Figure 1). Signs
occur soon after birth because affected pups are often ineffectual sucklers and must be
supplemented. As a result, they typically exhibit stunted growth. By 6 weeks of age, the
pelvic limbs may be advanced simultaneously and trismus is noted. Dogs subsequently
develop a progressively more stilted gait, atrophy of particularly the truncal and temporalis
muscles, a plantigrade stance due to hyperextension of the carpal joints and flexion at the
tibiotarsal joints, excessive drooling suggesting pharyngeal muscle involvement, and initial
lumbar kyphosis that progresses to lordosis. As with DMD, some muscles paradoxically
undergo hypertrophy. Aspiration pneumonia may occur due to pharyngeal or esophageal
muscle involvement. Cardiac failure due to cardiomyopathy can also occur.
Importantly, there can be marked variation in disease severity in GRMD, with some dogs
dying soon after birth due to extreme respiratory compromise and others demonstrating a
remarkably mild phenotype (Ambrósio et al 2008). In their early study of the clinical signs
of GRMD, Valentine et al suggested that homozygous females and smaller affected dogs
might have milder signs. Smaller beagle crosses with the GRMD mutation also may have a
less severe phenotype (Shimatsu et al 2003; Yugeta et al 2006). Supporting a potential
influence of either gender or body weight, female mdx mice have a milder phenotype
(Salimena et al 2004) and one DMD boy with growth hormone deficiency had less severe
Kornegay et al. Page 3













signs (Zatz et al 1981). Effects due to gender or body weight could influence interpretation
of GRMD preclinical studies in which both males and females of variable size are used.
With regard to body size, DMD treatment trials directed at reducing growth hormone have
failed to support a relationship with disease severity (Griggs et al 1990). Moreover, in a
separate GRMD study, lower growth hormone levels actually tended to correlate with a
more severe phenotype (de Lima et al 2007). In reviewing our own phenotypic data, we
found that larger GRMD dogs, if anything, have milder signs at 6 months of age. Tibiotarsal
joint angle and body weight correlated directly, indicating that larger dogs had less severe
postural instability. Larger GRMD dogs also had significantly smaller cranial sartorius
muscles and trended towards lower flexion force values, both of which predict a less severe
phenotype. This negative correlation between body size and phenotype likely reflects
stunting rather than cause and effect. We believe the milder clinical signs initially reported
in beagle crosses probably reflect the ameliorating effects of outbreeding, as Labrador
retrievers with the GRMD mutation also had a less severe phenotype (Miyazato et al 2011).
Similarly, in assessing the effects of gender in our own colony, results from phenotypic tests
did not differ between homozygous female and heterozygous male GRMD dogs (Kornegay
et al 2011). Thus, we have been unable to document an effect of either gender or body size
in GRMD.
Biomarkers in DMD and GRMD
To better utilize the GRMD model in therapeutic trials, we and others have developed
various phenotypic tests to objectively characterize disease progression. Results from
functional tests tend to correlate with one another and with other clinicopathologic features
(Figure 2). By comparing serial measurements from treated and untreated groups, one can
document improvement or delayed progression of disease. In keeping with the phenotypic
variation seen clinically, functional outcome values have also varied considerably, even
among dogs within the same litter, suggesting that modifier genes significantly influence the
phenotype (Kornegay et al 1994a, 1994b; Kornegay et al 1999). Importantly, phenotypic
variation confounds data analysis, requiring larger group sizes to demonstrate significance.
The effects of phenotypic variation on statistical analysis can be offset by establishing
baseline outcome values prior to treatment so that each dog serves as its own control. With
localized treatments, the effect of phenotypic variation is less of a concern because the
untreated opposite limb can serve as the control.
Composite and group severity scores—Composite scores that take into account
somewhat subjective numerical values assigned to particular clinical signs (Sampaolesi et al
2006; (Thibaud et al 2007); Rouger et al 2011) or overall disease phenotype (Ambrósio et al
2009) have been described and utilized in preclinical GRMD trials. With the composite
score method, a variety of postural and gait changes were assessed and scored 0, 1, and 2
(normal, mild, and severe). The scores were added to indicate the degree of dysfunction
(Sampaolesi et al 2006; Thibaud et al 2007). A later study used this same method but also
assigned scores for functional categories (ptyalism, breathing, etc) not directly related to gait
and posture (Rouger et al 2011). In another paper, dogs were subdivided into three
functional groups (mild, moderate, and severe) based principally on postural changes
(Ambrosio et al 2009). While these endpoints could have value in broadly categorizing
general therapeutic trends, additional more objective tests should be utilized to document
therapeutic gain.
Gait—Stephan Blot’s research group at Maisons-Alfort has utilized accelerometry to
objectively characterize the slow, short-stepped, and swaying gait of adult GRMD dogs
(Barthélémy et al 2009). Several quantitative indices, including total power, force and
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regularity of accelerations, stride length and speed (normalized for the dog’s height at the
withers), stride frequency, and cranio-caudal power were significantly decreased, while
medio-lateral power was increased, in GRMD versus normal dogs. Results tended to parallel
those achieved with composite clinical scores discussed above. A subsequent longitudinal
study showed that gait changes could be identified in GRMD dogs as early as 2 months of
age and then evolved with age (Barthélémy et al 2011).
We have assessed two-dimensional gait kinematics of the stifle and tibiotarsal joints in adult
GRMD dogs (Marsh et al 2010). They walked significantly slower and had more extended
stifle and less flexed tibiotarsal joints than normal dogs; range of motion was comparable in
the stifle but reduced in the tarsus. These changes should be interpreted in light of the joint
angle data collected at 6 months of age (discussed below). While the finding of greater
extension of the stifle is consistent with these data, the tibiotarsal joints of GRMD dogs
typically are more (rather than less) flexed. This discrepancy may relate to the differing ages
and phenotype of the two groups, as the kinematic data came from older, mildly-affected
dogs.
The 6-minute-walk test has become a standard outcome parameter in DMD patients
(MacDonald et al 2010) and has also been used to assess dogs with heart disease (Boddy et
al 2004). In their study of accelerometry, Barthélémy et al indicated that GRMD dogs had
difficulty completing the test. Our group has no experience with the 6-minute walk test.
Joint angles—We previously reported that 6-month-old GRMD dogs have abnormally
acute (contracted) tibiotarsal joint angles while positioned in dorsal recumbency for force
measurements (Kornegay et al 1994a, 1994b). Other investigators have subsequently
described methods to measure joint angles at maximal flexion and extension in normal dogs
(Jaegger et al 2002; Nicholson et al 2007). The method of Jaegger et al is now utilized to
measure pelvic limb joint angles for ongoing natural history and preclinical trials in our
laboratory. Based on our preliminary natural history findings collected at 6 months of age,
GRMD dogs tend to have more restricted maximal flexion of the hip joint (~ 60° normal vs.
~ 80° GRMD), increased maximal stifle extension (~145° normal vs. ~ 155° GRMD), and
more acute maximal tibiotarsal flexion (~ 45° normal vs. ~ 35° GRMD). To objectively
characterize the cranioventral shift of the pelvis typically seen in GRMD dogs, we also
measure the angle formed by two lines extending cranially from the tuber ischium, one
drawn parallel to the lumbar spine and the other extending to the midpoint of the tuber
coxae. Consistent with a previous report in which the pelvis was shown to shift into
essentially a vertical position in some severely-affected dogs (Brumitt et al 2006), this angle
has been larger in GRMD (~50°) versus normal (~ 35°) dogs at 6 months of age. While
these pelvic limb joint angle data are preliminary and correlations have not yet been
completed, we believe proximal joint and postural changes may contribute to the
characteristic plantigrade tarsal stance in GRMD, just as relative sparing of proximal flexor
muscles plays a role in distal limb flexor contractures in DMD (Vignos and Archibald 1960;
Siegel et al 1968). Indeed, cranial sartorius circumference corrected for body weight
correlates negatively with tibiotarsal joint angle, as measured by our original method
(Kornegay et al 2003). This suggests that the hypertrophied muscle might play a role
analogous to iliotibial band tightness in DMD (Rideau 1984).
Force/Torque measurements—We have demonstrated that GRMD dogs have
decreased strength of individual (Kornegay et al 1994a) and grouped (Kornegay et al 1999)
muscles. In our first study, tension was measured longitudinally in the peroneus longus,
using a tendon suture to secure the muscle to a transducer. Tension was clearly lower than
normal at 3 months of age but approached normal values by 6 months (Kornegay et al
1994a). Subsequent studies have focused principally on measurement of torque generated by
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the tibiotarsal joint (Kornegay et al 1999). For initial studies, force values were not corrected
for the lever arm (metatarsus) length, and were reported in Newtons. We now multiply the
force value by the length of the metatarsus (Newton-meters) (torque). The peroneal and
tibial nerves are stimulated percutaneously so that the paw pulls (peroneal nerve, flexion) or
pushes against (tibial nerve, extension) a lever interfaced with a force transducer. In our
initial study, force values were measured at 3, 4.5, 6, and 12 months of age. Absolute and
body-weight-corrected GRMD twitch and tetanic force values were lower than normal at all
ages (P<0.01 for most). However, tibiotarsal flexion and extension were differentially
affected. Flexion values were especially low at 3 months, whereas extension was affected
more at later ages. Several other GRMD findings differed from normal. The twitch/tetany
ratio was generally lower; post-tetanic potentiation for flexion values was less marked; and
extension relaxation and contraction times were longer. The consistency of GRMD values
was studied to determine which measurements would be most useful in evaluating treatment
outcome. Standard deviation was proportionally greater for GRMD versus normal
recordings. More consistent values were seen for tetany versus twitch and for flexion versus
extension. Left and right limb tetanic flexion values did not differ in GRMD; extension
values were more variable. These results suggested that measurement of tibiotarsal tetanic
flexion force should be most useful to document therapeutic benefit in GRMD dogs. Groups
of 15 and five would be necessary to demonstrate differences of 0.2 and 0.4 in the means of
treated and untreated GRMD dogs at 6 months of age, with associated powers of 0.824 and
0.856, respectively (Sigma Stat, Jandel Scientific, 2591 Kerner Blvd., San Rafael, CA,
USA). Values for extension force were more variable, suggesting that larger group sizes
would be required to demonstrate significance. However, extension force was used as an
outcome parameter to show that electromyographic (EMG) versus anatomic guided injection
of botulinum toxin achieved an ~ 20-25% greater effect (p < 0.05) in three normal beagle
dogs (Childers et al 1998). We have also demonstrated therapeutic benefit using both
increased extension (~ 60%) and paradoxical decreased flexion (~ 40%) (both p < 0.05) with
prednisone using a group size of six GRMD dogs (Liu et al 2004).
Eccentric contraction decrement—Dystrophin serves to buttress the muscle cell
membrane. In the absence of dystrophin, the membrane is prone to tearing during minimal
exercise. Dystrophic muscles are particularly prone to injury subsequent to eccentric
(lengthening) contractions (Edwards et al 1983). As an example, mdx mice have normal or
slightly-higher absolute force measurements but demonstrate greater-than-normal force
decrement after eccentric muscle contractions (Moens et al 1994). In an initial study of
GRMD dogs, we induced eccentric contractions in flexor muscles of the cranial tibial
compartment of the pelvic limb by stimulating the sciatic trunk in the mid-thigh area
(Childers et al 2002). This caused contraction of both the tibiotarsal joint flexors and
extensors. Because the extensors are more powerful, eccentric (lengthening) contractions
were induced in the flexors. More recently, we have developed a technique whereby the
common peroneal nerve is stimulated while simultaneously extending the tibiotarsal joint
with a servomotor (Aurora Scientific) coupled to a lever arm (Tegler et al 2011; Childers et
al 2011) (Figure 3). Movement of the lever arm is controlled by use of a computer and
customized LabView software (Aurora Scientific). Eccentric contractions are induced using
square wave pulses of 100 μsec duration in a tetanic run for 700 ms at a frequency of 50 Hz.
The contraction is held isometric at Lo for the first 500 ms. For the final 200 ms, the
muscles of the cranial tibial compartment are stretched by the servomotor at 0.5 Lo/s, such
that the muscles are displaced 0.1 Lo. Thus, the muscles of the cranial tibial compartment
are repeatedly stretched to induce mechanical damage. Three sets of 10 stretches are
performed. Each individual stretch is separated by 5 seconds and a four minute rest is
provided between the three sets. Contraction-induced injury is quantified by the force
(torque) deficit (Fd) using the following equation: Fd = (Po before stretch - Po after stretch /
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Po before stretch) × 100. We have shown that the decrement in normal dogs after 30
stretches does not exceed ~ 25%, while that of GRMD dogs can be as high as ~ 85% (Tegler
et al 2011). The sequence of decrement over the groups of contractions needs to be more
critically evaluated to determine the optimal point where normal and GRMD dogs can be
distinguished.
Cardiac Evaluation—Specific mutations in the dystrophin gene cause distinct cardiac
syndromes in DMD (Cox et al 1997; Muntoni 2003; Jefferies et al 2005; Connuck et al
2008), BMD (Nigro G et al 1995; Melacini et al 1996; Saito et al 1996; Holloway et al
2008), and X-linked dilated cardiomyopathy (XLDCM) (Ferlini et al 1999). The severity of
cardiac dysfunction in these conditions varies from subclinical disease to fatal congestive
heart failure. There tends to be an inverse relationship between skeletal and cardiac muscle
involvement (Saito et al 1996; Connuck et al 2008). DMD and BMD carriers may also have
cardiomyopthy (Hoogerwaard et al 1999; Holloway et al 2008).
Electrocardiographic (Moise et al 1991; Yugeta et al 2006), echocardiographic (Moise et al
1991; Chetboul et al, 2004; Yugeta et al 2006), radionuclide angiographic (Devaux et al
1993), cardiac MRI (Kellman et al, 2009), and cardiac pathologic (Valentine et al 1989a)
studies have been completed in dogs with GRMD. Additional longitudinal studies have been
completed in dogs expressing both the GRMD and Labrador retriever insertion mutations
(Fine et al 2011). Given that the dystrophin gene mutation can influence cardiac phenotype
(Jefferies et al 2005), it’s not clear whether changes in these dogs mirror those of GRMD.
GRMD dogs have ventricular arrhythmias and increased Q/R ratios due to characteristic
deep Q waves on ECG evaluation (Moise et al 1991; Yugeta et al 2006); evidence of
ventricular dilation and decreased fractional shortening, together with increased
echogenicity that corresponds to mineralization at necropsy, with two dimensional and M-
mode echocardiography (Moise et al 1991; Yugeta et al 2006); decreased radial and
longitudinal left ventricular motions with tissue Doppler imaging (Chetboul et al, 2004); and
myocardial fibrosis and mineralization on pathologic evaluation as early as 6.5 months of
age (Valentine et al, 1989a). Electrocardiographic changes are seen at 6 months and progress
with age (Moise et al 1991; Yugeta et al 2006). Ventricular measurements and shortening
fraction determined with two dimensional and M-mode echocardiography are usually within
the normal range over the first two years of life (Moise et al 1991; Yugeta et al 2006). The
original echocardiographic studies done by Moise et al identified areas of increased
echogenicity within the posterobasal left ventricular wall in 6-month-old GRMD dogs, with
progression over time to the apex of the heart (Moise et al 1991). Areas of increased
echogenicity were not seen in a later study of 6- to 21-month-old GRMD dogs crossed to
beagles, (Yugeta et al 2006) in keeping with a trend for outbreeding to lessen severity of the
GRMD phenotype (Kornegay et al, 2011). On pathologic evaluation, fibrosis is most
pronounced in the left ventricular papillary muscle and apical left ventricular free wall
(Valentine et al 1989a). Fatty deposition in seen in older dogs. Mineralization appears to be
more pronounced than in DMD. Analogous ECG and echocardiographic changes progressed
over the course of 3, 6, and 12 month evaluations in the GRMD-Labrador retriever muscular
dystrophy crossbred dogs, suggesting that such markers can be used in preclinical trials
(Fine et al 2011).
Working with investigators at NHLBI, we have completed preliminary cardiac MRI studies
on two GRMD dogs and a Welsh corgi with the intron 13 insertion mutation (Kellman et al
2009). These studies focused on defining the degree of fibrosis and fat deposition within the
myocardium using multi-echo Dixon methods both pre- and post-late gadolinium
enhancement (LGE) and a segmented phase sensitive inversion recovery (PSIR) turbo
FLASH sequence. Retrogated cardiac cine true-fast imaging with a steady-state precession
(FISP) sequence was used to assess left ventricular function. Intramural fat was clearly seen
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with pre-contrast, fat-separated images. Corresponding hyper-enhanced lesions were noted
with LGE. Intramural fibrosis, distinguished from fat on the LGE water phase image, was
also evident. Left ventricular ejection fractions were reduced in the two GRMD dogs (22%
and 26%) and normal in the Welsh corgi (53%), approximating values seen with
echocardiography (Table 2).
We have conducted cardiac evaluations, including ECG and echocardiography, on 11
GRMD dogs ranging from 7 months to 9 years of age at North Carolina State University
(Kornegay JN et al, unpublished) (Table 2). Most were breeding males without clinical heart
disease; nine had abnormalities on ECG and/or echocardiography (Figure 4). A diagnosis of
dilated cardiomyopathy (DCM) was made in seven of them. Several dogs had systolic
murmurs best heard in the left apical area. Sinus arrhythmia, occasional premature
ventricular contractions, prolonged (> 60 ms) QRS complexes, and deep Q waves were
noted on ECG. Structural and functional changes were seen with echocardiography. In
particular, the myocardium was mottled, consistent with fatty deposition and fibrosis, and
there was cardiomegaly, as evidenced by chamber dilation/enlargement. Functional indices,
such as fractional shortening and ejection fraction, were often decreased. Two of the dogs
had mitral regurgitation. Several of the dogs with DCM have been treated with ACE
inhibitors (enalapril), β blockers (atenolol), and/or phosphodiesterase inhibitors
(pimobendan).
We saw acute death, presumably due to an arrhythmia, in a GRMD carrier that had dramatic
myocardial fibrosis at necropsy. This prompted us to complete a prospective study of
cardiac function, including Holter monitoring and necropsy of a group of GRMD carriers.
Some dogs had dramatic ventricular arrhythmias and all had myocardial fibrosis at necropsy
(Kane et al submitted).
Cardiac pathologic studies have been performed on a number of GRMD dogs from our
colony that died or were euthanized. Gross and histologic findings have been consistent with
those described previously (Valentine et al, 1989a). Cardiomegaly, due particularly to left
ventricular dilation, is seen grossly. Mineralization and focal to generalized fibrosis are
present on histologic evaluation.
Skeletal muscle magnetic resonance imaging (MRI)—MRI has been used
increasingly to provide meaningful data on the natural history and response to therapy of a
number of diseases, including DMD (Lamminen 1990; Liu et al 1993; Marden et al 2005;
Lovitt et al 2006). Principal MRI changes in DMD include an increase in T2 and decrease in
T1 relaxation times due to accumulation of fat in affected muscles and an associated
increase in whole body fat and decrease in muscle mass. Objective grading systems allow
data to be compared over the course of the disease (Lamminen 1990; Liu et al 1993). Results
from these grading systems have correlated with those of clinical functional tests. One serial
study suggested that MRI is more sensitive than functional tests in predicting disease
progression (Liu et al 1993). MRI has also been used to monitor DMD disease progression
in treatment trials (Karpati et al 1993; Miller et al 1997).
The potential role of MRI as a biomarker in GRMD has been reported in both natural history
and preclinical papers. In the first study, the thoracic limbs of 2-month-old GRMD and
normal dogs were scanned at 4 T (Thibaud et al 2007). GRMD dogs had an abnormally-high
T2-weighted/T1-weighted signal ratio, greater T2-weighted image heterogeneity, and more
pronounced signal enhancement post-contrast. An additional study of 3-month-old GRMD
dogs showed increased signal intensity on T2-weighted images in which the fat signal was
suppressed, increased T2 values, and greater enhancement with gadolinium, all consistent
with inflammation associated with early necrosis (Kobayashi et al 2009). T2 signal was
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decreased in GRMD dogs treated systemically with morpholinos compared to age-matched
untreated dogs, supporting the notion that MRI can be used to track improvement in
longitudinal studies (Yokota et al 2009). An additional study showed that increased signal
on T2-weighted images could be used to track sites of AAV-micro-dystrophin construct
injection (Wang et al 2010). As discussed further below, we have also seen increased signal
intensity in muscles associated with an apparent innate immune response in dogs treated
with AAV-9 and a codon-optimized human mini-dystrophin (Kornegay et al 2010).
Moreover, MRI has been used to track the distribution of fluid in dogs treated with AAV-
mini-dystrophin constructs delivered by regional limb delivery.
We have completed MRI studies in ~ 50 GRMD dogs (Wang et al 2011; Kornegay JN et al,
unpublished). Some of these have been longitudinal studies and others have been at single
time points. Consistent with published studies, signal-intense lesions presumably
corresponding to fluid accumulation in necrotic lesions have been seen on fat suppressed,
T2-weighted images in younger dogs, while increased fat deposition has been seen at later
ages (Figure 5). The severity of these changes has varied among muscles. We have been
particularly interested in assessing volumetric and T2 signal values longitudinally in GRMD
dogs between 3 and 12 months of age, as this time frame has most commonly been used for
preclinical studies by our group and others. Water and fat values are calculated separately on
T2-weighted images, so as to gain insight on their relative contribution to the T2 signal (data
not reported here).
Preliminary results have been evaluated in five GRMD and 10 age-matched normal dogs in
which six proximal pelvic limb muscles (semitendinosus, rectus femoris, cranial sartorius,
adductor magnus, gracilis, and biceps femoris) were evaluated as part of an ongoing natural
history study. T2 values were higher than normal in each of the six GRMD muscles at all
ages and these values declined in both groups from 3 to the 9-12 month age group (Table 3;
Figure 6). Body-weight-corrected muscle volumes varied, with the GRMD cranial sartorius
being markedly larger than normal at 6 and 9-12 months (Table 4), as we have previously
reported (Kornegay et al 2003). The GRMD semitendinosus muscle was also larger, while
the rectus femoris and biceps femoris were smaller. Body-weight-corrected volumetric
values for the gracilis and adductor muscles were comparable in GRMD versus normal
dogs.
Electromyographic and single fiber studies—Electromyography (EMG) can be used
to objectively characterize muscle in both natural history and treatment studies. As with
other myopathies, DMD is characterized by small, polyphasic, short-duration motor unit
potentials (MUPs), with associated spontaneous activity ranging from fibrillation potentials
to complex repetitive discharges (CRDs) (Buchthal et al 1963; Desmedt and Borenstein
1976; Emeryk-Szajewska and Kopeć 2008). EMG was performed in the two original GRMD
dogs studied by our group at 3, 5, 7, and 34 months of age (Kornegay et al 1988). There
were persistent, spontaneous, high-frequency discharges of constant amplitude, with
frequency components of up to 2000 Hz on power spectral analysis. In a subsequent study to
which we contributed, seven GRMD dogs produced in the Cornell colony were evaluated
between the ages of 6 weeks and 5.5 years of age (Valentine et al 1989b). Spontaneous
activity, consisting primarily of CRDs, positive sharp waves, and polyphasic potentials, was
found in all dogs, particularly after 10 weeks. Motor unit potentials were of short duration
and polyphasic. Abnormalities were rare at 6 weeks but easily detected at 8 to 10 weeks.
Taken together, these changes were consistent with those seen in DMD. However, the CRDs
were much more prominent in affected dogs.
Details of MU architecture and function are not adequately quantified by conventional
EMG. In contrast, quantitative EMG (Nandedkar et al 1995) allows one to map objective
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motor unit parameters over the natural course of disease or in response to treatment. Despite
these diagnostic advantages, quantitative measures of the motor unit have not been assessed
in animal models of muscular dystrophy and only on a limited basis in DMD patients. In an
ongoing natural history study, we have performed concentric needle EMG and multi-motor
unit potential (Multi-MUP) analysis on the cranial sartorius, cranial tibialis, gastrocnemius
lateral head, and vastus lateralis muscles of a total of 10 GRMD and 15 normal dogs
between 2 months and 4 years of age (Bhavaraju-Sanka R, Kornegay JN, and Howard JF,
unpublished). Data collected included presence and severity of spontaneous activity and
MUP amplitude, duration, turns, phases and polyphasicity. GRMD dogs exhibited
widespread complex repetitive discharges at all ages that often made it hard to perform
multi-MUP analysis. When data from all ages were compared, multi-MUP analysis showed
reduced MUP duration and amplitude with smaller MUP areas in GRMD versus controls. In
comparing data from three each GRMD and normal dogs at 2-3 and 9-12 months age,
differences in MUP duration and area were evident at both ages, while amplitude
normalized somewhat in the older dogs.
Single fiber EMG (SFEMG) action potentials can be recorded from individual muscle fibers
(Hilton et al 1985; Sanders and Stalberg 1996). Two particular parameters, jitter and fiber
density, offer insight into mechanisms contributing to neuromuscular disease. Jitter refers to
the variable speed with which nerve impulses are transmitted across motor endplates and is
typically expressed as the mean of consecutive differences (MCD) of interpotential
intervals. Up to 40% of DMD patients have increased jitter, due presumably to abnormal
motor endplates associated with diseased or regenerating muscle fibers (Sanders and
Stalberg 1996; Hilton et al 1985). Fiber density is defined based on the number of individual
myofiber action potentials recorded at one time with the SFEMG electrode. DMD patients
have increased fiber density, most likely as a function of myofiber proliferation/regeneration
in response to the dystrophic process (Hilton et al 1985; Sanders and Stalberg 1996).
Building on an earlier study of SFEMG in normal dogs (Hopkins et al 1993), we have
assessed stimulation (s)SFEMG in the peroneus longus and cranial tibialis muscles of most
of the dogs included in the quantitative EMG studies (Figure 7). Dogs were anesthetized and
ten to twenty fibers were recorded from each muscle and neuromuscular jitter (MCD) was
measured. The affected dogs exhibited increased jitter in both muscles, with MCD values of
~ 30 versus ~ 15 msec in normal dogs. There was also more impulse blocking in the affected
dogs. In addition, an increase in the fiber density estimate was inferred by the greater
number of action potentials at each stimulation site [data not presented; see Figure 7].
Pathologic studies—Gross and histopathologic lesions vary remarkably among
dystrophin-deficient muscles (Kornegay et al 1988; Valentine et al 1990; Childers et al
2001; Nguyen et al 2002; Kornegay et al 2003). At the light microscopic level, there is a
pattern of small group myofiber necrosis and regeneration, which is typical of dystrophin-
deficient muscular dystrophy across species. Fiber size variation occurs due to the combined
effects of individual myofiber hypertrophy and a marked increase in small regenerating
fibers. Necrotic myofibers typically are in various states of degeneration, ranging from
swollen, granular (so-called hyaline or hypercontracted) myofibers that stain intensely
eosinophilic with H&E to fragmented fibers that are undergoing necrosis and mineralization
(calcification), with an associated infiltrate of macrophages (myophagocytosis) and other
mononuclear inflammatory cells. As necrotic material is removed by the monocyte-
marcrophage system, only the basal lamina of affected myofibers may remain, resulting in
empty sarcolemmal tubes. On longitudinal section, necrosis occurs segmentally along the
length of the myofiber, in keeping with the domain of individual nuclei. Regenerating fibers
tend to occur in clusters, often closely associated with areas of necrosis, and are small with
prominent nuclei/nucleoli and basophilic cytoplasm. Sarcolemmal nuclei may be located
centrally within the myofiber (so-called central or internal nuclei) rather than peripherally.
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On histochemical stains, type II fibers are preferentially affected, with an associated
predominance of type 1 fibers and fiber type grouping (Kornegay et al 1988). Intermediate
fiber types, apparently reflecting immaturity associated with regeneration, occur commonly
in neonatal GRMD muscles (Nguyen et al 2002). In a prednisone preclinical trial in GRMD,
we attributed reduced numbers of fetal-myosin positive fibers in treated dogs to a reduction
in necrosis and accompanying decrease in demand for regeneration (Liu et al 2004) Electron
microscopic changes evident in affected fibers include disruption of myofibrillar
organization, dilatation of sarcoplasmic reticulum, increasedglycogen, and both hyperplasia
and hypertrophy of mitochondria (Kornegay et al 1988; Valentine et al 1990).
The pattern of muscle involvement must be carefully considered in assessing functional and
pathologic results from preclinical trials. As with DMD and the mdx mouse, the extraoccular
muscles are largely spared in GRMD (Valentine et al 1990; Nguyen et al 2002). In sharp
contrast, muscles that are used heavily in utero and early in life, such as the tongue,
diaphragm, and limb flexors (including the sartorius, semitendinosus, and cranial tibialis),
demonstrate acute necrosis (Valentine et al 1990; Nguyen et al 2002). Other muscles are
spared early in life and develop lesions later. This delayed pattern of necrosis is more typical
of extensor muscles, which presumably do not become severely affected until dogs begin
walking and muscles such as the quadriceps femoris experience eccentric contractions.
Interestingly, the rectus femoris responds differently than the other three heads of the
quadriceps, as it shows severe early lesions, probably because of its origin from the pelvis
and dual role as a hip flexor and stifle extensor. The long digital extensor of the pelvic limb
also has a dual function as a digital extensor and tibiotarsal flexor. Unlike the cranial tibialis
which is a strict tibiotarsal flexor and undergoes moderate (Nguyen et al 2002) to severe
(Valentine et al 1990) necrosis in neonates, the long digital extensor was unaffected in one
study of GRMD neonatal lesions (Nguyen et al 2002). Thus, again, the flexor function
seemed to drive the pattern of early necrosis.
Muscles that undergo early necrosis may then regenerate and even hypertrophy. This pattern
is perhaps best represented by the cranial sartorius. We have shown it seemingly recovers
remarkably from the initial necrosis and then can reach two to three times normal size when
corrected for body weight (Kornegay et al 2003). Based on morphometric histological
studies, the cranial sartorius demonstrates true hypertrophy in dogs aged 4-10 months.
Muscle is then replaced by fat and connective tissue, giving a pattern more in keeping with
the pseudohypertrophy that has classically been described in DMD. Recent imaging studies
in DMD have suggested that some muscles, including the sartorius (Marden et al 2005), are
relatively spared or even hypertrophied. Moreover, the gastrocnemius, which has typically
been thought to exhibit pseudohypertrophy, may initially undergo true hypertrophy in some
patients (Cros et al 1989). We believe true hypertrophy of the cranial sartorius and other
muscles may have clinical significance, in that imbalances between differentially-affected
agonist and antagonist muscles can contribute to contractures (see earlier discussion under
joint angles).
Use of the GRMD model in treatment development for DMD
Preclinical trials
Potential treatments for DMD may be broadly categorized as molecular, cellular, or
pharmacologic (Chakkalakal et al 2005; Goyenvalle et al 2011). The two most common
molecular approaches are gene therapy, whereby the dystrophin gene is introduced into
muscle either locally or through the vasculature, generally through use of plasmids or viral
vectors; and gene correction, which involves introduction of oligonucleotides (chimeric or
antisense) to induce either inherent repair mechanisms or exon skipping to reestablish the
correct nucleotide sequence (reading frame). With cell-based therapies, normal cells such as
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myoblasts or stem cells are transplanted into diseased muscle. Pharmacologic approaches do
not deliver the defective gene and/or protein to the diseased muscle(s). Instead, specific
pathogenetic mechanisms that contribute to the dystrophic phenotype are targeted. Examples
include compounds that reduce inflammation (NF-κB inhibition), increase muscle mass
(insulin-like growth factor, myostatin inhibition), read through stop codons in the defective
dystrophin gene (aminoglycoside antibiotics), or increase production of utrophin (the
autosomal homologue of dystrophin). Essentially all preclinical studies conducted thus far in
dystrophin-deficient dogs have been completed in the GRMD model (Table 5).
Plasmid- and vector-based gene therapy—Howell et al showed that GRMD
myofibers can be transduced for at least 14 days using plasmids containing full length
dystrophin and mini-dystrophin cDNA (Howell et al 1998a). Adenovirus-mediated mini-
dystrophin (Howell et al 1998b) and utrophin (Cerletti et al 2003) transfer have also been
achieved in immunosuppressed GRMD dogs. In other GRMD studies, dystrophin minigene
transfer with an adeno-associated virus (AAV) vector was limited by a marked immunologic
response to viral capsid antigens (Wang et al 2007a) that could be blocked with brief
immunosuppression (Wang et al 2007b). Others have suggested that the immune response
occurs against components of the construct, including dystrophin itself (Yuasa et al 2007).
We have completed a series of studies of AAV-mini-dystrophin constructs in GRMD dogs
to simultaneously extend mdx studies (Wang et al 2009) and clarify the source of the
immune response in GRMD dogs (J Li, JR Bogan, DJ Bogan, JN Kornegay, and X Xiao,
unpublished). Our initial studies focused on demonstrating the immunologic reaction to
constructs. A total of 6 GRMD and 8 normal dogs were injected intramuscularly with AAV1
or 2 constructs containing the Lac-Z reporter gene or human mini-dystrophin gene.
Preliminary data from direct muscle injection showed a greater immunologic reaction than
that encountered in the mdx mouse. The degree of immunologic reaction was reduced when
the canine versus human mini-dystrophin gene was used. These results indicated that direct
intramuscular injection of AAV1 and 2 vectors caused a marked immune response not
observed in mice, suggesting species differences to AAV-mediated local intramuscular gene
transfer.
We have subsequently delivered similar AAV-based mini-dystrophin gene constructs via an
afferent transvenular retrograde extravasation (ATVRX; regional limb) method for somatic
gene transfer to muscles with favorable results. A total of 33 (20 normal and 13 GRMD)
dogs have been injected using various constructs and perfusion volumes/rates. AAV-8 or 9
and canine mini-dystrophin have been used in the most recent studies (Li et al 2009).
Widespread mini-dystrophin gene expression has been seen in muscles of the perfused limb
without immunosuppression, establishing the utility of AAV-mediated regional limb therapy
in GRMD. The distribution of the perfusion fluid has been mapped with MRI (Figure 8).
Some of these dogs have also been evaluated with the functional biomarkers discussed
above. Isometric tibiotarsal extension force was intermediate between GRMD and normal
natural history values in three GRMD dogs treated with AAV-8 or 9-minidystrophin
constructs. Values had also normalized somewhat in the contralateral limb, suggesting a
systemic effect (see further below). However, the degree of eccentric contraction decrement
did not improve in the treated GRMD dogs. The remarkable differences in cellular immunity
between local intramuscular injection and vasculature-mediated regional limb gene transfer
by AAV vectors suggest that the gene delivery route is an important factor to be considered
for clinical studies. With these promising results, a parallel phase 1 safety study of regional
limb delivery of saline was initiated in adult muscular dystrophy patients (Fan et al 2011).
This study has demonstrated overall safety, with minimal side effects.
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Ultimately, gene therapy strategies must extend to systemic delivery to achieve widespread
muscle transduction. Initial canine studies have utilized neonatal dogs in an effort to
minimize the immune response and achieve widespread delivery. Working with the Duan
laboratory, we demonstrated widespread muscle transduction of a human placental alkaline
phosphatase reporter gene carried by an AAV-9 vector administered intravenously without
immunosuppression (Yue et al 2008). Subsequently, in collaboration with Xiao Xiao,
GRMD dogs given a single intravenous injection of an AAV9 vector carrying a human
codon-optimized human mini-dystrophin gene showed generalized muscle transduction in
~15% to nearly 100% of myofibers (Kornegay et al 2010). However, these pups showed
delayed growth and pelvic limb muscle atrophy and contractures, seemingly due to an innate
immune response, exacerbated by the use of a high dose of codon-optimized human mini-
dystrophin. Marked increased signal intensity, compatible with inflammation, was seen with
T2-fat suppressed MRI in the vastus heads of the quadriceps femoris and adductor muscles
of these dogs. Analogous selective involvement of the vastus heads, with sparing of the
rectus femoris, is seen in humans with sporadic inclusion myositis (Phillips et al 2001).
Similarly, dogs with Neospora caninum infection develop hyperextension of the stifle (knee)
(genu recurvatum) secondary to quadriceps myositis and contractures (Knowler and
Wheeler 1995). Surprisingly, with some of the older GRMD dogs receiving mini-dystrophin
via regional limb delivery, there was dramatic body-wide mini-dystrophin gene expression,
apparently due to leakage beyond the tourniquet (Li et al 2009). This prompted us to initiate
studies of systemic AAV-mini-dystrophin gene delivery in GRMD dogs at a few months of
age. Preliminary results have been promising, as widespread and persistent gene expression
was seen in one dog treated with an AAV-9 mini-dystrophin construct.
Gene repair—Chimeric oligonucleotides were used to induce normal host cell mismatch
repair mechanisms to correct the splice site mutation in a GRMD dog (Bartlett et al 2000).
Antisense oligonucleotides (morpholino) given intravenously in three GRMD dogs
(Japanese beagle cross) over a period of up to 5.5 months resulted in functional and
pathologic improvement, plus reduced T2 signal intensity on MRI (Yokota et al 2009). A
limited clinical trial of a mopholino-based exon skipping strategy in DMD patients showed
modest dystrophin expression in muscle fibers (Cirak et al 2011).
Cell-based therapies—While much attention has shifted to viral based gene therapy,
there continues to be considerable interest in cellular approaches, in part because of the need
for cell replacement in more chronic cases. A variety of adult, fetal, and embryonic stem
cells can potentially contribute to regeneration of diseased muscle. Myoblasts and their
parent satellite cells were the obvious choice for initial studies. Partridge et al showed that
donor myoblasts could fuse with host cells in a murine muscle injury model (Partridge et al
1978) and restore dystrophin expression in the mdx mouse (Partridge et al 1989). Human
DMD clinical trials were ultimately conducted in the 1990’s (Tremblay et al 1993; Miller et
al 1997). Follow-up studies of treated patients didn’t show functional gains, although some
donor cells could be detected in the muscles (Gussoni et al 1997). Further clinical trials were
halted. The limited success of these trials could be attributed to a high degree of initial cell
death due presumably to the combined effects of poor blood supply to the injected cell bolus
and immune rejection, plus limited migration of the surviving injected cells (Tremblay et al
1993; Fan et al 1996; Gussoni et al 1997; Smythe et al 2001; Partridge 2002; Skuk et al
2007).
We characterized canine myoblasts and conducted transplantation studies in the GRMD
model during the 1990s (Prattis et al 1993; Nakagaki et al 1994a, 1994b). However, we were
unable to achieve significant implantation of myoblasts in GRMD dogs. In the context of
these studies, we developed an autologous myoblast transplantation model in which cells
were labeled with fluorescent microspheres and injected in preirradiated 3-month-old,
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normal dogs as part of a cocktail that included the muscle toxin notexin and methylene blue.
In subsequent studies at 7 and 24 days post-transplantation, large groups of injected cells
formed fascicles and expressed ATPase (Figure 9), providing support for the general
principle that myoblasts could implant and differentiate in dogs (Kornegay et al 1992).
Bone marrow provides a paradigm for an accessible and pluripotent stem cell population.
Despite promising results in mdx mice (Corti et al 2002), bone marrow stem cell (BMSC)
transplantation did not restore dystrophin expression in affected dogs (Dell’Agnola et al
2004). While there was successful allogeneic bone marrow engraftment, BMSCs did not
contribute either skeletal muscle or muscle precursor cells. Other adult stem cell cell
populations may contribute to muscle regeneration. Mesoangioblasts are mesodermal stem
cells derived from the vascular wall that contribute to muscle regeneration in both mice and
dogs (De Angelis et al 1999; Sampaolesi et al 2006). These cells are multipotent, with
capacity to give rise to osteogenic, adipogenic, myogenic, and endothelial lineages (Minasi
et al 2002). The Cossu laboratory showed that a clinically-relevant cell mass can be obtained
for transplant into the GRMD model and that mesoangioblasts injected in the femoral artery
gained access to muscle through downstream capillary beds (Sampaolesi et al 2006). GRMD
dogs treated with mesoangioblasts had immunohistochemical and Western blot evidence of
dystrophin expression. However, questions have been raised about the outcome parameters
used and the role that immunosuppression may have played in improvement (Bretag 2007).
Human immature dental pulp stem cells were transplanted by either arterial or muscular
injections into four young GRMD littermate dogs (Kerkis et al 2008). Cell implantation,
chimeric fibers, and minimal dystrophin expression were seen. In two recent studies from
this same group, muscular implantation was achieved after systemic administration of
umbilical cord mesenchymal stromal cells (MSCs; intra-arterial) (Zucconi et al 2011) and
human-adipose-derived stromal cells (hASCs; (intravenous) (Vieira et al 2011) in GRMD
dogs. Immunosuppression was not used in either study. Donor-recipient pairs were matched
for the dog leukocyte antigen (DLA; major histocompatibility complex) in the MSC study
but not for hASCs. While dystrophin was evident with hASCs, there was no expression with
MSCs. In another study, intraarterial delivery of allogenic muscle stem cells led to long-term
dystrophin expression and apparent stabilization of pathologic lesions and clinical function
in three GRMD dogs (Rouger et al 2011).
Pharmacological therapies—The GRMD model has been used less commonly for
pharmacologic approaches. Perhaps because of the perceived lower risk of such treatments,
there has been a tendency to go directly from mdx mouse studies to human trials. In
preparation for high-dose and early-treatment regimens of prednisone that might be
impractical in human patients, we showed that a dose of 2 mg/kg, orally once daily for 4
months from 2 to 6 months of age, increased extensor muscle force in GRMD dogs, while
causing a paradoxical decrease in flexor force (Liu et al 2004). The reduced flexor force
probably occurred due to a reduction in early necrosis and a less pronounced regenerative
response that can otherwise lead to functional hypertrophy. Treated dogs had remarkable
myofiber mineralization, raising questions about potential deleterious side effects. Perhaps,
most importantly, this prednisone preclinical trial established the 2 to 4 month time frame as
an appropriate window for conducting pharmacologic studies in GRMD dogs.
Using GRMD dogs provided by our group, the Metzger laboratory demonstrated that
chronic infusion of membrane-sealing poloxamer reduced myocardial fibrosis, blocked
increases of serum cardiac troponin I and brain type natriuretic peptide, and prevented left-
ventricular remodeling (Townsend et al 2010). A reduction in GRMD versus mdx mouse
cardiac myocyte compliance was associated with a lack of utrophin upregulation in affected
dogs, perhaps providing insight for their more severe cardiac phenotype. These results
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indicated that poloxamer may serve as an effective membrane-stabilizing chemical surrogate
in dystrophin/utrophin deficiency.
Se-Jin Lee and colleagues have shown that the myostatin gene (growth/differentiation factor
8) is a key negative regulator of muscle growth (McPherron et al 1997; Lee et al 1999; Lee
2000; McPherron and Lee 2002). Dystrophin-deficient mdx mice in which myostatin is
knocked out (Wagner et al 2002) or inhibited postnatally (Wagner et al 2005) have a less
severe phenotype. Based, in part, on these results, there has been increasing interest in
treatments to inhibit myostatin and thus promote muscle growth in DMD and other muscle
wasting disorders. We investigated whether myostatin blockade could be achieved by an
AAV-8-canine myostatin propeptide construct in two normal 3-month-old dogs treated via
regional limb delivery (Qiao et al 2009). AAV vector DNA and propeptide gene expression
were detected by quantitative polymerase chain reaction, Western blotting, and
immunofluorescence staining of muscle biopsies. Over expression of the myostatin
propeptide resulted in enhanced muscle growth, as evidenced by larger myofibers in
multiple muscles and increased muscle volume on MRI. Separately, using four each treated
and control 9 to 10-month-old GRMD dogs provided by our group, the Sweeney laboratory
studied the muscle effects of liver directed gene transfer of a self-complementary AAV-8
vector expressing a myostatin peptide (Bish et al 2011). Treated GRMD dogs had increased
muscle mass as assessed by MRI and confirmed by necropsy, together with hypertrophy of
Type IIA fibers and reduced serum creatine kinase and muscle fibrosis. Independently, we
have crossbred dystrophin-deficient GRMD dogs with whippets carrying a spontaneous two
nucleotide myostatin gene deletion (Moscher et al 2007). A total of four dystrophic,
myostatin-heterozygous GRippets and three dystrophic myostatin wild type dogs from two
litters have been evaluated at 6 to 8 months of age using various phenotypic tests discussed
above. Rather than showing improvement, the dystrophic myostatin-heterozygous GRippets
were more severely affected than their dystrophic myostatin-wild type littermates,
apparently because disproportionate enlargement and atrophy/hypoplasia of certain muscles
led to postural instability and joint contractures (Kornegay JN et al, unpublished).
The calpain and ubiquitin-proteasome systems are involved in muscle degradation.
Inhibition of involved enzymes has been proposed as a treatment for DMD, based largely on
evidence that enzyme activities are elevated in the mdx mouse and that blockade can
improve their phenotype (Spencer et al 1995; Badalamente and Stracher 2000; Bonuccelli et
al 2007). We evaluated the efficacy of a novel calpain inhibitor in 6-week-old GRMD dogs
treated daily with either active compound (n=9) or placebo (n=7) for 8 weeks (Childers et al,
in press). Several tests were performed at baseline and every two weeks over the course of
therapy. Calpain inhibition did not improve tibiotarsal joint angle, increase tibiotarsal
extension force, or reduce eccentric contraction decrement; furthermore, there was no
improvement in lean muscle mass or muscle histopathologic changes. Thus, consistent with
findings from a recent mdx mouse study (Selsby et al 2010), we were unable to demonstrate
efficacy for calpain inhibition in the GRMD model. Separately, in collaboration with the
Willis laboratory, we have measured mRNA expression of ubiquitin-proteasome and calpain
system components and calpain 1 and 2 and proteasome activities in several GRMD muscles
and the heart at 6 months of age (Wadosky et al 2011). Less than half of the muscles tested
had increases in proteasome activity and only half had increased calpain activity. Moreover,
numerous components of the ubiquitin-proteasome system were significantly decreased in
the heart. These results illustrate that ubiquitin-proteasome and calpain system expression
varies among skeletal muscles and the heart, suggesting that pharmacological inhibition
could lead to unexpected consequences. mRNA studies.
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Potential role for modifier genes in DMD and GRMD
Symptoms in DMD patients vary even though most completely lack dystrophin, regardless
of the specific gene mutation (Beggs et al 1991; Winnand et al 1993). Microarray gene
expression profiling in DMD and dystrophin-deficient animals has provided a platform to
study the role of modifier genes in phenotypic variation. Initial studies in both the mdx
mouse (Porter et al 2002) and DMD (Chen et al 2000; Haslett et al 2003) have generally
shown up-regulation of genes associated with inflammation and the regenerative response.
With the advent of canine microarrays (Holzwarth et al 2005), analogous studies have been
done in dogs with various diseases (Clements et al 2007). However, to our knowledge,
expression arrays have not been evaluated in GRMD. As discussed above, we have collected
functional data from GRMD dogs, both in the context of natural history and preclinical
treatment studies. We also have muscle biopsy samples from many of these dogs.
Importantly, these samples have been collected systematically from the same muscles at
similar ages. Thus, by correlating expression array and functional data from these dogs, we
should gain insight into the role that modifier genes play in phenotypic variation at both the
individual dog and muscle level. In an ongoing study, we have performed 72 microarray
profiles on the cranial sartorius, long digital extensor, and vastus lateralis muscles of eight
GRMD and four normal dogs at 4-9 weeks and 6 months of age to evaluate mRNA
expression on a genome-wide level. So as to determine genes that could protect against the
dystrophic phenotype, we identified specific transcripts of the dystrophin-glycoprotein
complex that were associated with cranial sartorius size at 6 months of age. Follow-up
immunofluoresent microscopy revealed expression of these proteins in the perimembranous
region in all three muscles despite the lack of dystrophin. We were interested in identifying
additional genes that could be driving muscle hypertrophy. Using quantitative PCR to
confirm the array studies, targeted genes involved with muscle growth were confirmed to be
differentially expressed within each muscle. In conclusion, expression profiling of multiple
skeletal muscles revealed unique patterns of transcript expression in each muscle, suggesting
specific molecular signatures in response to the primary molecular defect (Figure 10).
Therapies that target these genes could be beneficial in DMD.
Conclusion
Unlike the dystrophin-deficient mdx mouse, which remains relatively normal clinically,
GRMD dogs develop progressive, fatal disease strikingly similar to the human condition. To
better utilize the GRMD model in therapeutic trials, we and others have developed various
phenotypic tests to objectively characterize disease progression. The availability of these
tests has set the stage for use of GRMD dogs in preclinical trials. Indeed, as outlined in this
review, the GRMD model has been used in a range of genetic, cellular, and pharmacologic
studies, setting the stage for clinical trials in DMD.
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Figure 1. Characteristic plantigrade stance in GRMD dog at 6 months of age
Pelvic limbs are shifted forward. The angle formed by the flexor surface of the tibiotarsal
joint (black lines) is approximately 110° versus the 140° angle of normal standing dogs.
There is hyperextension of the carpus.
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Figure 2. Correlations among phenotypic tests in GRMD dogs
Scattergrams with regression lines drawn to show correlations between tibiotarsal joint angle
(vertical axis in both) and body-weight-corrected tibiotarsal joint isometric tetanic extension
(A) and flexion (B) force in 51 GRMD dogs at 6 months of age. Joint angle correlates
strongly (p < 0.0001) with both parameters. The correlation is direct (r is positive) for
extension force and inverse (r is negative) for flexion force.
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Figure 3. Eccentric contraction decrement
A. Left pelvic limb of a 6-month-old GRMD dog immobilized in a stereotactic frame, with
needles (covered by tape) positioned to stimulate the peroneal nerve. B. Histogram showing
mean torque (N-m) generated by tetanic tibiotarsal joint flexion during a series of 10 tetanic
contractions. At the conclusion of each tetanic contraction, these maximally-stimulated
cranial tibial compartment muscles were forcibly stretched by the servomotor as the
tibiotarsal joint was extended a further 30 degrees (see D). The mean value of the initial
contractions (blue bar) was ~ 1.4 N-m, while the tenth contraction (red bar) was ~ 0.2 N-m,
representing an 85% decrement. C. The characteristic tetanic mechanical potential produced
by tibiotarsal joint flexion is illustrated. D. The tenth single tetanic mechanical potential of
the series is followed by a sharp further deflection due to the eccentric contraction induced
by the servomotor, with an immediate return to baseline.
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Figure 4. GRMD cardiac studies
M-mode echocardiogram from a 4-year-old, male GRMD dog (left; Dog 2 in Table 2)
showing a marked reduction in ventricular contractility at systole compared to a normal dog
(right). Measurements from M-mode study for GRMD dog for Diastole/Systole: IVS 0.55
cm/0.88 cm; LV 5.75 cm/4.46 cm; LVPW 0.68 cm/0.86 cm; LV Vol 163.1 ml/90.6 ml. LV
FS = 22.4%. LV EF = 44.4%.
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Figure 5. GRMD MRI Studies
The four panels from left to right are MRI images from a 2-month-old GRMD carrier
(A,C,E,G) and affected littermate (B,D,F,H) and 5-year-old GRMD carrier (I,K,M) and
affected dog (J,L,N). A, B, I, and J are TSE-fat percentage and C, D, K, and L are TSE-fat
saturation. Transverse sections of muscle have been segmented in E, F, M, and N for region-
of-interest measurements and are shown in three dimensions in G and H (2-month-old dogs
only). Note, particularly, the signal-intense lesions in several muscles in D and J,
representing fluid accumulation, acutely, and fatty change, chronically, respectively. Signal-
intense lesions seen in J reverse with fat saturation in L. Segmentation was done using ITK-
SNAP (http://www.itksnap.org/pmwiki/pmwiki.php) (Yushkevich et al 2006).
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Figure 6. T2 maps from GRMD and normal dogs
Comparison of the mean intensity of the cranial sartorius (A) and rectus femoris (B) muscles
in T2 map of 5 GRMD (blue lines) and 10 normal littermates (red lines), at 3, 6, and 9-12
months of age. GRMD values tend to be higher at each age in both muscles but those for the
cranial sartorius overlap with normal at 6 months and even more so at 9-12 months.
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Figure 7. Representative sSFEMG potentials from the peroneus longus muscle from normal (A)
and GRMD (B) dogs
The normal dog has minimal neuromuscular jitter and only a few action potentials at the
acquisition site, while the GRMD dog has increased neuromuscular jitter and multiple action
potentials.
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Figure 8. MRI 50 minutes after limb perfusion of an 11-week-old GRMD dog
T2-weighted TSE MR images without (A) and with (B, C) fat saturation. Composite images
have been created to orient the left and right limbs in the same plane. As a result, some
proximal structures such as the colon are duplicated. Craniocaudal (top) and transverse
(bottom) sections proximal to the stifle are seen in A and B. In each image, the perfused
limb is on the left. Increased signal intensity is consistently seen in the perfused limb.
Intensity could be either fat or fluid in A but is due to fluid alone in the fat saturation images
in B and C. Intensity is greatest in the distal third of the femur and is particularly prominent
in the biceps femoris muscle which is highlighted in C. In the fat saturation images in C, the
perfused (red) and non-perfused (green) biceps femoris muscles were segmented for
quantitative measurements. The volume and signal intensity of the biceps femoris were
proportionally higher in the perfused versus non-perfused limb. Segmentation was done
using ITK-SNAP (http://www.itksnap.org/pmwiki/pmwiki.php) (Yushkevich et al 2006).
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Figure 9. Autologous myoblast transplantation model in normal dogs
Cells were injected percutaneously (A, right); methylene blue identifies sites of injection (A,
left). Large aggregates of cells containing fluorescent microspheres are forming fascicles
(circles in B and C). Muscle fibers in these fascicles stain with ATPase (pH 9.4) (B) and
toluidine blue (left image in C and D) and contain fluorescent microspheres (right image in
C and D) at 24 days post-transplantation.
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Figure 10. Heat map of unsupervised hierarchical clustering showing differential transcript
expression between GRMD and normal profiles
The heat map was prepared from 72 mRNA profiles from the cranial sartorius (CS), long
digital extensor (LDE), and vastus lateralis (VL) muscles of eight GRMD and four normal
dogs at 4-9 weeks and 6 months of age. Four hundred transcripts that were differentially
regulated between GRMD CS profiles versus normal CS profiles (p < 0.0001; 200
transcripts) and GRMD LDE profiles versus normal LDE profiles (p < 0.0001; 200
transcripts) were clustered against the 72 mRNA profiles. Two main clusters are outlined in
yellow. The top yellow cluster shows up-regulated genes (red color) for GRMD VL, CS and
LDE and some normal VL profiles on the left and down-regulated transcripts (green) to the
right of the white dotted lines. The bottom yellow cluster shows the opposite for all normal
profiles. The profiles in between the yellow outlined clusters (VL GRMD and VL normal
box) show a similar clustering pattern as the GRMD CS and normal VL profile box within
the top yellow cluster. Note that there is some heterogeneity within GRMD profile
expression. The heat map was prepared in HCE 3.5 Power Analysis; http://
bioinformatics.cnmcresearch.org.
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Table 1
DMD Gene Mutations in Dogs
Breed Mutation Reference
Golden retriever Splice site point mutation, with skipping of exon 7 in transcript Sharp et al, 1992
German shorthaired pointer Deletion encompassing the entire dystrophin gene Schatzberg et al, 1999
Rottweiler Nonsense point mutation in exon 58 Winand et al, 1994
Cavalier King Charles spaniel Splice site point mutation, with skipping of exon 50 in transcript Walmsley et al, 2010
Pembroke Welsh corgi Insertion in intron 13 Smith et al, 2011
Labrador retriever Insertion in intron 19 Smith et al, 2007; current paper
Cocker spaniel Four nucleotide deletion in exon 65 Current paper
Tibetan terrier Deletion of exons 8-29 Current paper
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Table 5
Preclinical Treatment Trials in GRMD Dogs
Plasmid and Vector-Based Gene Therapy
Plasmid/full length dystrophin and mini-dystrophin Howell et al 1998a
Adenovirus/mini-dystrophin Howell et al 1998b
Adenovirus/utrophin Cerletti et al 2003
AAV/mini-dystrophin Wang et al 2007a, b; Yuasa et al 2007; Kornegay et al 2010
Gene Repair
Chimeric oligonucleotides Bartlett et al 2000
Antisense oligonucleotides Yokota et al 2009
Cell Therapy
Hematopoietic stem cells Dell’Agnola et al 2004
Mesoangioblasts Sampaolesi et al 2006
Dental pulp cells Kerkis et al 2008
Muscle stem cells Rouger et al 2011
Human adipose-derived mesenchymal stromal cells Vieira et al 2011
Umbilical cord mesenchymal stromal cells Zucconi et al 2011
Pharmacologic
Prednisone Liu et al 2004
Membrane-sealing poloxamer Townsend et al 2010
AAV/myostatin peptide Bish et al 2011
Calpain inhibition Childers et al in press
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